Last reviewed · How we verify
mycophenolate mofetil or azathioprine
Mycophenolate mofetil and azathioprine are immunosuppressive drugs that inhibit the enzyme inosine monophosphate dehydrogenase (IMPDH), which is necessary for the proliferation of T and B lymphocytes.
Mycophenolate mofetil and azathioprine are immunosuppressive drugs that inhibit the enzyme inosine monophosphate dehydrogenase (IMPDH), which is necessary for the proliferation of T and B lymphocytes. Used for Prevention of organ rejection in patients with kidney, liver, or heart transplants, Treatment of certain autoimmune diseases, such as lupus nephritis and myasthenia gravis.
At a glance
| Generic name | mycophenolate mofetil or azathioprine |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Drug class | Immunosuppressant |
| Target | Inosine monophosphate dehydrogenase (IMPDH) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting IMPDH, these drugs reduce the production of guanosine nucleotides, which are essential for the proliferation of lymphocytes. This action suppresses the immune system, making it less likely to reject transplanted organs. Additionally, by reducing the number of lymphocytes, these drugs also decrease the production of antibodies, which can contribute to inflammation and tissue damage.
Approved indications
- Prevention of organ rejection in patients with kidney, liver, or heart transplants
- Treatment of certain autoimmune diseases, such as lupus nephritis and myasthenia gravis
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Leukopenia
- Anemia
- Thrombocytopenia
- Neutropenia
Key clinical trials
- This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer (PHASE4)
- Different Immunosuppressive Treatment in iMN (PHASE3)
- Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (PHASE4)
- Weaning of Immunosuppression in Nephritis of Lupus (PHASE3)
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (PHASE2)
- Micophenolate Mofetil Versus Azathioprine in Myocarditis (PHASE3)
- Adalimumab vs. Conventional Immunosuppression for Uveitis Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: